Elanco Animal Health Incorporated reported $5.02B of revenue over the trailing twelve months, +12% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $5.02B (to Q2 2026). Net income: −$199M, trailing twelve months to Q2 2026. Free cash flow: $379M, trailing twelve months to Q2 2026. EPS: −$0.41, trailing twelve months to Q2 2026.

ELANElanco Animal Health Incorporated

Healthcare

$22.92+19% 1Y

$22.92

$18.5452 weeks$26.84

ELAN as reported

Elanco Animal Health Incorporated reported $5.02B of revenue over the trailing twelve months, +12% on the year before. 11 reported series are charted on this page, each one as filed.

$5.02B

Revenue, trailing twelve months · to Q2 2026 · +12% against the twelve months before

Net income: −$199M
Net income · −146% year on year · trailing twelve months to Q2 2026
Free cash flow: $379M
Free cash flow · +5.0% year on year · trailing twelve months to Q2 2026
EPS: −$0.41
EPS · −148% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for ELAN, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$5.02B	+12%	Q2 2026
Net income	−$199M	−146%	Q2 2026
EPS	−$0.41	−148%	Q2 2026
Gross margin	55%	n/a	Q2 2026
Operating margin	12%	n/a	Q4 2024 · 6 quarters behind
Net margin	−4.8%	n/a	Q2 2026
ROE	−2.4%	n/a	Q2 2026
ROA	−1.2%	n/a	Q2 2026
ROIC	−2.7%	n/a	Q4 2024 · 6 quarters behind
Free cash flow	$379M	+5.0%	Q2 2026
P/E	21.4	n/a	Q2 2025 · 4 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.